



(51) International Patent Classification:

C07D 471/08 (2006.01) A61K 31/4545 (2006.01)
A61K 31/439 (2006.01) A61K 31/4709 (2006.01)
A61K 31/444 (2006.01) A61K 31/496 (2006.01)

(21) International Application Number:

PCT/IB2012/002675

(22) International Filing Date:

11 December 2012 (11.12.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(71) Applicant: NAEJA PHARMACEUTICAL INC.
[CA/CA]; 4290-91A Street, Edmonton, Alberta T6E 5V2
(CA).

(72) Inventors: MAITI, Samarendra N.; 1828-104 Street, Ed-
monton, Alberta T6J 5G7 (CA). NGUYEN, Dai; 4928-13
Avenue, Edmonton, Alberta T6L 6J9 (CA). KHAN, Je-
hangir; 504 Hunters Way, Edmonton, Alberta T6R 2W1
(CA). LING, Rong; 126 Farnell Close NW, Edmonton,
Alberta T6R 2E3 (CA).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,


AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β -LACTAMASE INHIB-
ITORS



(57) Abstract: A compound of formula (I),
wherein: M is hydrogen or a pharmaceutically
acceptable salt-forming cation; Y is OR¹ or
NR²R³, and R¹, R², R³ and M are as defined
herein. Also, methods of treating bacterial in-
fection, pharmaceutical compositions, mo-
lecular complexes and processes for preparing
compounds.